27 December, 10:26
Remdesivir
Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
In response Vincent Kennedy⍟ to his Publication
Does anyone have the video link. I can't see the slides only hear the voice. Vider is too small. When zoomed it is very pixelated.
I also do not see the NIH study or Gilead study links the presenter referenced. These may support the presenters conclusions, but without them we don't know.
IMHO, listening to the video alone, you really can't conclude if people died from remdesivir or ebola. The slides or studies might contain that data.
Has anyone dug on Remdesivir?
What, I Think I know about remdesivir is
-- They blocked access to HCQ and used a fake lancet report
-- They blocked access to Ivermectin
-- They use ventilators and remdesivir
-- HCQ and Ivermectin are cheap. Ventilators and Remdesivir are not.
-- There are multiple doctors that have released their field results on HCQ and Ivermectin.
I also do not see the NIH study or Gilead study links the presenter referenced. These may support the presenters conclusions, but without them we don't know.
IMHO, listening to the video alone, you really can't conclude if people died from remdesivir or ebola. The slides or studies might contain that data.
Has anyone dug on Remdesivir?
What, I Think I know about remdesivir is
-- They blocked access to HCQ and used a fake lancet report
-- They blocked access to Ivermectin
-- They use ventilators and remdesivir
-- HCQ and Ivermectin are cheap. Ventilators and Remdesivir are not.
-- There are multiple doctors that have released their field results on HCQ and Ivermectin.
Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396
In 2020 From NIH article. Not sure if this is the one the presenter was referencing.
Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated.
https://www.ncbi.nlm.nih.g...
Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated.
https://www.ncbi.nlm.nih.g...
The journey of remdesivir: from Ebola to COVID-19
Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250494/
03:12 PM - Dec 28, 2021
In response mars 1776 to his Publication
Only people mentioned by mars_1776 in this post can reply
